5. Progressive supranuclear palsy Clinical trials / Disease details
Clinical trials : 95 / Drugs : 119 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000036522 | 2019/04/15 | 16/04/2019 | Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug | Investigator-initiated clinical trial for progressive supranuclear palsy using an anti-cholinergic drug - Clinical trial for PSP using anticholinergic drug | Progressive supranuclear palsy | Trihexyphenidyl hydrochloride max.3mg for 3 months Placebo max. 3mg for 3 months | 1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya Hospital | NULL | Recruiting | 40years-old | Not applicable | Male and Female | 32 | Not selected | Japan |